Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, I wonder how many shares Les’s biz guys have gotten. I bet it’s millions.
Do you know what in the heck he did to get 24 million shares, if anything. did the company buy out his company or something like that? Why does he have 24 million shares. So now, right when we’ve submitted, he can shove it down our throat by selling.
Ok didn’t know that.
And if he doesn’t come clean and tell us this, then, one can assume that he is actually allowing his shares to be loaned and shorted, all the while management is telling us stupid retails to lock up our shares.
For the most part predated LP
Yes, agree Mahalik needs to go. If he was involved in the absolutely stupid Swiss deal, that’s horrible.
Literally the Swiss debacle, is absolutely the worst thing. This company has ever done and is absolutely Horrible, eventhough it is historically dated now the most part predict LP. It’s darn embarrassing Embarrassing and unprofessional.
And I agree I’ve been working my ass off buying on the open market with hard earned money, and have just a microscopic amount compared to Mahalick. And all he’s done is write a sweet piece in 2007 and involve the Company in the Swiss Fraud
And now he’s selling. He needs to come clean and tell us openly that he’s not allowing his 24 million shares to be borrowed and shorted against us. Linda needs to clean house and get his ass off the board.
Exactly. Really makes me mad especially when insiders are selling and also possibly?? Using their enormous shares to be loaned out for shorting. All the while telling others not to. I think Mahalik needs to come clean and tell us that he is not doing that.
Thanks Soj
I do appreciate your post. I don’t understand a lot of the technical stuff with charting but I do appreciate your interpretations.
Thanks for talking me off of the cliff!
Be careful with putting me on ignore. Sometimes I come up with some pretty good stuff but not recently.
Agree thanks thanks!
Poor Man. Thanks I do agree.
Not stupid angry. Watching people die.
Short off Bull
Thanks thanks. Good info. So now we know the share price will be $.40-$.60 for the next four years with no incentive for management to do anything. they can just continue deluding for four more years until they hit the shelf. Good to know.
Mani you are correct absolutely nothing has the ability to impact share price. Absolutely nothing.
We’ve already had so many great things like the jam article, survival advantage, no, side effects, Eden, etc. etc. etc. and nothing, Nada, absolutely nil effect on value and share price. So absolutely, the nature article will have no effect as well. Nothing does nothing can. KG has it pretty well locked down forever.
And management will never partner will never ask for help. Will never do anything like that. Control freaks it seems.
Thanks agree.
But it doesn’t seem like we are seeing as retail any improvements in any value irrespective of anything that the company, achieves, milestones made, anything, literally anything,the company has absolutely no effect on stock price.
I don’t think management understands or cares about this at all and I’m not sure management is actually working with us and for us.
They may have their eye on a different ball, something that is decades away, that never pans out for us. They must think that human beings are immortal. And that investments should be immortal As shareholders.
I don’t know but nothing they do seems to affect stock price at this point in time. Nothing but pressure. Pressure all the time no improvement no sustainability. Nothing. Never. No good news affect it. nothing affect it. At all. Totally discordant behavior.
So Smitty if the share place has been beaten down, because of insiders loaning their enormous number of shares that are shorted? That’s irrelevant so the losses to the stock are related to that and not spoofing? That spoofing really didn’t cause the reduction in the price of the stock? so that’s irrelevant according to you. Isn’t one of the items of the lawsuit to figure out how much was lost by the activity? Please advise.
True, true.
WHAT???
The FDA actually did something!
Must’ve been some money exchanged, and somewhere along the line to grease it. Seems like that’s the only thing that works with the FDA.
Thanks I needed that reinforcement. Everybody was starting to beat up on me. I thought I was like Biden or Trump or something and didn’t understand what I was reading!
Smitty, not New at all. Owned this sucker for over 10 years now. Never seems to work out. No matter what they do.
X be nice, don’t laugh at me!
Am I miss reading the 10K then that Malik has 24,807 288 shares owned? It didn’t say options.
I think the defendants lawyers would love to know if this was true or not. If it was true, they’d have a hay day in court about it if the insiders were doing this sort of malicious stuff. It would essentially be a get out of jail, free card for the defendants.
I know, you’re right, however, even when we get news, like the last PR, which was very very good; nothing absolutely nothing except reduce on the price. So even news and milestones are meaningless for this thing.
Agreed Jester and probably psychotic, but when I did the math calculations, the math works for that analysis in terms of the amount of money one would need to cover their tax liability from interest income on their loaned out shares. Worked out very close but you’re right I’m probably psychotic. I’m just kind of wondering why someone would sell right beforethey submit for approval and why in the hell has the share price had absolutely no strength never ever no matter what the milestones and no matter what the company does.
Agree probably not the case but I’m also wondering what unbelievably powerful force is keeping the shares down. 24 million shares would keep it down if they were loaned out and shorted.
Question for the board. I’m wondering if insiders that own shares can have their shares in a brokerage account and allow them to be lent out and then they get interest income on the shares that are lent out to hedge funds who most likely short the stock. Is that something insiders can do? Legally? Does anyone know?
I’m wondering if the insider sale by Navid Malik was supposedly was due to a tax liability. But yet he didn’t sell any shares prior to that that would’ve given him a text liability, so how could he have any tax liability? Perhaps something else, I don’t know, but he certainly didn’t get any tax liability from holding NWBO stock.
I got thinking that maybe he needed to sell them in order to pay the tax liability on the interest that he made from his broker loaning out his 24 million shares to the shorts, mathematically, it turns out that that is approximately the amount of money he would need to cover taxes.
Just wondering, because I found it odd that an insider would sell right before the drug is submitted for approval; kind of weird isn’t it?
Any thoughts on this or do you think it’s crazy?
I’m just trying to figure out if management truly is on our side or not.
Just wondering if anyone has any insight why we’re just now starting to use GMP materials and hiring a consultant to use GMP materials. It seems to me that given the nature of this work, with cellular growth and treatment for patients one would’ve used GMP practices and materials from the very beginning instead of Now in the ninth inning saying oh, we have to hire somebody to do and make sure we’re doing GMP materials and methods. Any thoughts on this?
Just got today’s print version JAMA.
Interesting opinion, peace regarding CAR, T cell therapy. Turns out they found a rare instance in which pediatric patients who received CAR T developed a T cell lymphoma and the lymphoma in questions contained the CAR construct. This means that the drug product itself has transitioned into a malignancy.
Glad DC VAX doesn’t have to worry about that because it uses the patient’s own and cells. Just a little interesting sidenote.
Some chat poop on GMP!
When a biotech company is building a device to grow cells, the use of Good Manufacturing Practice (GMP) grade materials ensures that the products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
GMP covers all aspects of the manufacturing process: defined manufacturing processes, validated critical manufacturing steps, suitable premises, equipment, materials and personnel, clear and detailed SOPs, instructions and records, and systematic reviews of batch and overall quality.
For a biotech company, the use of GMP grade materials in cell cultivation devices can provide several benefits:
1. **Consistent Quality**: GMP ensures that the materials used are of high quality and do not introduce contaminants that could affect cell growth.
2. **Regulatory Compliance**: Many regulatory bodies require the use of GMP grade materials in devices used for cell cultivation, especially if the cells are intended for therapeutic use.
3. **Risk Minimization**: Using GMP grade materials can help minimize risks associated with contamination, variability, and other issues that can compromise the integrity of the cell culture.
As for the cost, GMP grade materials are generally more expensive than regular materials, due to the rigorous quality control, testing, and documentation associated with their production. However, the increased cost should be weighed against the benefits of improved quality and compliance with regulatory requirements. The exact cost can vary widely based on the specific materials and their source.
It's also important to note that while initial costs for GMP grade materials can be higher, they can potentially save a company significant costs in the long run by reducing the risk of product recalls, regulatory fines, and damage to the company's reputation.
When a biotech company is building a device to grow cells, the use of Good Manufacturing Practice (GMP) grade materials ensures that the products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
GMP covers all aspects of the manufacturing process: defined manufacturing processes, validated critical manufacturing steps, suitable premises, equipment, materials and personnel, clear and detailed SOPs, instructions and records, and systematic reviews of batch and overall quality.
For a biotech company, the use of GMP grade materials in cell cultivation devices can provide several benefits:
1. **Consistent Quality**: GMP ensures that the materials used are of high quality and do not introduce contaminants that could affect cell growth.
2. **Regulatory Compliance**: Many regulatory bodies require the use of GMP grade materials in devices used for cell cultivation, especially if the cells are intended for therapeutic use.
3. **Risk Minimization**: Using GMP grade materials can help minimize risks associated with contamination, variability, and other issues that can compromise the integrity of the cell culture.
As for the cost, GMP grade materials are generally more expensive than regular materials, due to the rigorous quality control, testing, and documentation associated with their production. However, the increased cost should be weighed against the benefits of improved quality and compliance with regulatory requirements. The exact cost can vary widely based on the specific materials and their source.
It's also important to note that while initial costs for GMP grade materials can be higher, they can potentially save a company significant costs in the long run by reducing the risk of product recalls, regulatory fines, and damage to the company's reputation.
Your comparison does highlight a key point about the difference between GMP grade materials and their non-GMP counterparts. In a hospital setting, products like a Q-tip would indeed be more expensive, not because they are fundamentally different from what you might buy at a drugstore, but because they must meet stringent quality control and documentation standards to ensure they are sterile, safe, and suitable for medical use.
It's not about "gaming the system," but rather about ensuring the highest standards of safety and efficacy. The additional cost of GMP products reflects the increased manufacturing, testing, and documentation efforts required to meet regulatory standards, which in turn helps to ensure patient safety.
The same principle applies in the biotech industry. GMP grade materials, such as cell culture media, are more expensive because they are manufactured under strict conditions that ensure their quality and safety, especially when the end product is intended for therapeutic use. To put it simply, the use of GMP grade materials reduces the risk of product failure, contamination, and potential harm to patients.
In the end, while GMP materials are indeed more costly, they provide a level of assurance that can be vital in sensitive environments like healthcare settings or biotech manufacturing facilities.
I don’t miss him. He can stay in his shell! Too much emotion.
But what about kosher bacon? Would they eat that?
Very nice AE. But I’m wondering if we’ll run into problems because I don’t think that there is that many time intervals where there wasn’t spoofing just saying.
Problem for us is that KG and his active managers have been trying to drive the price of our company stock to zero because apparently they must think that’s the Correct valuation! And they can’t be wrong, correct!! oh, OK now I understand.
From his own lab, and with his own experience from melanoma work. I think it’s great. It may definitely lead to something if it works. But it would require a trial of more than one in it.
OK did he really say that? He did not think DC VAX works? I think not. That’s why he’s looking at other immune therapies. He knows that immune therapy does work. He just wants to perhaps use a new way of achieving the efficacy of immunotherapy.
Nothing else new that is approved works!
Under?????? JAMA is not decent??
Not necessarily. He probably doesn’t have the secret sauce on how they develop DC VAX so was unable to have his lab develop it.
Also, it probably furthers the research in his own lab to try a new approach and that’s what he’s looking for. That’s perhaps more effective. Who knows. But I think it’s good that he’s looking at different things. But he is definitely not saying with this that DC VAX doesn’t work that’s a big overstatement in my opinion.